ASC 730 R&D Accounting: Expensing, Exceptions, and Disclosures

Under ASC 730, R&D accounting works on a single default rule: expense research and development costs in the period you incur them. No capitalization, no deferral, no waiting to see whether the project pans out.¹ Two narrow exceptions matter in practice: assets acquired for R&D that have alternative future uses get capitalized, and in-process R&D picked up in a business combination sits on the balance sheet instead of hitting the income statement. Everything else about applying the standard is working out which costs belong in the R&D bucket and how to disclose the total.

What Counts as R&D

The standard splits qualifying activity into two phases. Research is the early work of generating new knowledge: laboratory experiments, testing product concepts, and exploring applications for new findings. Development translates that knowledge into a plan or design for a new or significantly improved product, process, or service, including designing and testing prototypes, building pre-production models, and evaluating design alternatives.

Classification turns on the nature of the activity, not where it sits on the org chart. An engineer running experiments on a factory floor is doing R&D just as much as a scientist in a dedicated lab. The question is whether the work aims to generate new knowledge or convert that knowledge into something the company can use or sell.

Plenty of technical work falls outside the standard. Quality control testing during regular production, routine product checks, market research, post-production troubleshooting, and adapting an existing product to a specific customer’s needs are not R&D. Those costs go into cost of goods sold or operating expenses. Several other categories are carved out by scope and governed by different standards:

R&D performed under contract for another party follows contract accounting, not ASC 730.
Internal-use software follows ASC 350-40.
Prospecting, exploring, drilling, and mineral development follow extractive industry standards.
R&D acquired in a business combination follows ASC 805 and ASC 350.

The Immediate Expensing Rule

The outcome of an R&D project is irrelevant to the accounting. A cost expensed today is expensed whether the project produces a blockbuster next year or gets shelved in six months. The rationale is that at the time you’re spending the money, there is no reliable way to measure whether future economic benefits will materialize, and GAAP takes the conservative position of keeping speculative assets off the balance sheet. It also removes the temptation to selectively capitalize R&D to smooth or inflate reported earnings.

The contrast with property, plant, and equipment is intentional. PP&E gets capitalized because the future benefits are predictable and measurable; R&D spending, by its nature, doesn’t offer that same assurance.

Which Costs Go Into R&D Expense

The R&D line on the income statement is a composite. Each category follows its own measurement rules, and how you build the number affects both financial reporting and tax positions later.

Materials and Supplies

Materials, parts, and supplies consumed in R&D are included in R&D expense at cost. Purchase materials specifically for a project and use them up during the period, and the full cost is expensed immediately. Materials purchased but not yet consumed stay on the balance sheet as inventory or prepaid assets until you actually use them. Only the consumed portion moves to R&D expense.

Personnel Costs

Salaries, wages, benefits, payroll taxes, and stock-based compensation for employees engaged in R&D all belong in R&D expense. When someone splits time between R&D and other functions, allocate based on documented time records. Only the portion directly attributable to R&D gets charged.

Indirect Costs

Overhead that supports the R&D function, such as utilities, facility maintenance, and insurance for an R&D lab, must be allocated using a rational, consistently applied method. General and administrative costs that don’t directly relate to R&D stay out. The line can be blurry for shared facilities, but the principle is to capture only costs necessary to support the R&D work itself.

The Alternative Future Use Exception

The immediate expensing rule has a significant carve-out for assets that can serve purposes beyond the current project. This test applies to both tangible and intangible assets, and it is where much of the practical complexity in ASC 730 lives.

Tangible Assets

Equipment or facilities acquired for R&D that could also be used in other projects or operations get capitalized as PP&E rather than expensed at acquisition.² You depreciate them over their useful life, and only the depreciation allocable to R&D use during the period runs through R&D expense.

If a tangible asset is acquired for a single R&D project and has no use beyond it, the entire cost is expensed immediately.² A general-purpose testing machine gets capitalized; a custom fixture built for one experiment does not.

Intangible Assets

Purchased intangibles like patents, licenses, and technology rights follow a similar logic with one twist. When an intangible acquired for R&D has an alternative future use, it gets capitalized, but it’s treated as indefinite-lived for as long as the associated R&D activities continue.³ During that period, you don’t amortize it; you test it for impairment annually. Only after the R&D effort is completed or abandoned do you set a useful life and start systematic amortization.

Purchased intangibles with no alternative future use get expensed at acquisition, same as single-purpose tangible assets.³ Payments to another entity to perform R&D services on your behalf are not purchased intangibles for this purpose, even if the work generates intellectual property.

In-Process R&D Acquired in a Business Combination

The mandatory expensing rule has its biggest exception when a company acquires in-process R&D through a business combination. IPR&D often represents projects that haven’t reached completion and have no alternative future use, exactly the kind of spending that would be expensed immediately if generated internally.

Despite that, IPR&D acquired in a business combination is recognized separately from goodwill at the acquisition date and recorded at fair value under ASC 805.⁴ Determining that fair value typically involves projections of the discounted cash flows the project is expected to generate if completed. The rationale for allowing capitalization is that an arm’s-length acquisition price provides objective evidence of value.

Once on the books, IPR&D is classified as an indefinite-lived intangible. It is not amortized but must be tested for impairment at least annually.⁴ What happens next depends on the project’s outcome. When the project is completed, the IPR&D asset is reclassified as a definite-lived intangible and amortized over its estimated useful economic life. When the project is abandoned, the carrying amount is written off as an impairment loss.

The asymmetry matters. Two identical R&D projects can receive dramatically different financial statement treatment depending on whether the company developed the work internally or acquired it. Internal R&D immediately reduces current earnings, while acquired IPR&D sits on the balance sheet and affects future earnings through amortization or impairment.

Funded and Contracted R&D

ASC 730-20 addresses arrangements where someone else is paying for the R&D, or you are funding R&D performed by a third party.

When a company performs R&D under a contract for another entity and the costs are reimbursable, those costs fall outside ASC 730. The performing entity accounts for them under its contract accounting policies rather than expensing them as R&D. The economic risk sits with the funding party, not the performer.

The funding entity’s accounting depends on the structure. If repayment of a loan or advance to the performing party depends solely on the R&D producing future economic benefits, the funding entity treats those payments as its own R&D costs and expenses them when incurred. Nonrefundable advance payments for future R&D services are deferred initially, then recognized as R&D expense as the services are performed. If at any point delivery of the goods or services becomes improbable, the remaining advance is expensed immediately.

What Has to Be Disclosed

ASC 730 requires disclosure of total R&D costs charged to expense for each period presented on the income statement.⁵ The amount can appear as a separate line on the face of the income statement or in the notes. Beyond the total dollar figure, disclose the accounting policy for distinguishing between R&D costs that are expensed and any costs capitalized under the alternative future use test, and address the treatment of significant purchased tangible or intangible assets used in R&D.

Public companies face an additional layer under ASC 280, the segment reporting standard. As updated by ASU 2023-07, entities must disclose significant expense categories for each reportable segment when those expenses are regularly provided to the chief operating decision maker and included in reported segment profit or loss. Where R&D is a major spending category, that often means reporting R&D expense by business segment rather than only a consolidated total.

Where GAAP and Tax Diverge

Book and tax treatment of R&D no longer line up cleanly, and it’s worth knowing the boundary because ASC 730 itself doesn’t control what happens on the tax return. Under GAAP, all R&D is expensed immediately. For federal tax purposes, Section 174 requires foreign R&D expenditures to be capitalized and amortized over 15 years starting at the midpoint of the tax year in which the costs are incurred.⁶ The One Big Beautiful Bill Act, enacted in 2025, created new Section 174A permanently restoring immediate deduction of domestic research and experimental expenditures for tax years beginning after December 31, 2024, with an election available to capitalize and amortize domestic R&D over at least 60 months. Any company with overseas R&D operations will carry a book-tax difference.

Software development also gets special tax treatment. Any amount paid or incurred for software development is treated as a research or experimental expenditure under Section 174, which can differ from the GAAP treatment for the same costs.⁶

Software Development Sits in a Different Framework

Software costs are one of the most common sources of confusion because they are largely outside ASC 730’s scope. Software developed for external sale or licensing follows ASC 985-20: all costs before technological feasibility are expensed as R&D, and costs after that point are capitalized until the product is ready for market. Internal-use software follows ASC 350-40, where capitalization begins when management authorizes and commits funding to the project and completion and intended use are probable. Once either threshold is met, the costs leave ASC 730’s world entirely, which is why software companies often capitalize a substantial share of development spending that would be expensed immediately if the same work involved a physical product.

1
FASB. Research and Development (Topic 730) – ASC 730-10-25-1
2
FASB. Research and Development (Topic 730) – ASC 730-10-25-2(a)
3
FASB. Research and Development (Topic 730) – ASC 730-10-25-2(c)
4
Deloitte Accounting Research Tool. Roadmap: Business Combinations – Intangible Assets
5
Internal Revenue Service. FAQs – IRC 41 QREs and ASC 730 LBI Directive
6
Office of the Law Revision Counsel. 26 USC 174 – Amortization of Research and Experimental Expenditures